What is Celularity's market cap?

Celularity (CELU) has a market capitalization of $21.6M and trades on NASDAQ.

Who are Celularity's competitors?

Celularity's key competitors include Organogenesis Holdings Inc., Longeveron, Mimedx Group, Inc., and others. These companies compete in similar markets and product categories.

Who does Celularity partner with?

Celularity's notable partners include BioCellgraft, Inc., Defeye, Inc., Celeniv Pte. Ltd..

What subsidiaries does Celularity have?

Celularity's subsidiaries include CariCord Inc..

Where is Celularity headquartered?

Celularity is headquartered in United States of America and employs approximately 225 people. It has been publicly traded since 2021.

Celularity

CELU

Celularity is a clinical-stage biotechnology company that develops off-the-shelf allogeneic cellular therapies and advanced biomaterial products derived from the postpartum human placenta.

Market cap

$21.65M-58.2%

Table of contents

Earnings

Q1 2026 report

May 8, 2026

EPS-$0.59

Read the full report

Next report

Aug 12, 2026 (in a month)

Competitors

By market cap

Gilead Sciences$167.41B+20.4%

MiMedx Group$616.6M-35.6%

Century Therapeutics$416.6M+779%

Fate Therapeutics$362.5M+198%

Organogenesis Holdings Inc.$316.5M-41.3%

Nkarta, Inc.$229.7M+91.5%

Celularity$21.6M-50.3%

Longeveron$20.6M+6.2%

By revenue growth

Organogenesis Holdings Inc.+12.2%

MiMedx Group+10.5%

Gilead Sciences+3.5%

By net margin

Gilead Sciences30.99%+10.2pp

MiMedx Group7.88%-3.5pp

Organogenesis Holdings Inc.0.528%+4.0pp

Profile

Celularity is a clinical-stage biotechnology company that develops off-the-shelf allogeneic cellular therapies and advanced biomaterial products derived from the postpartum human placenta. The company leverages its proprietary IMPACT platform to target age-related degenerative diseases, cancer, and infectious disorders by harnessing the unique immunological properties of placental cells. Its core value proposition lies in providing scalable, affordable, and readily available regenerative treatments designed to extend human healthspan.

Competitive position

Celularity is a pioneer in placental-derived allogeneic therapies, utilizing a fully integrated end-to-end manufacturing platform to produce off-the-shelf treatments with superior scalability compared to autologous cell therapies.

GeographiesUnited States, Global

Customer segmentsHealthcare providers, Consumers, Biopharmaceutical companies

Business modelProduct manufacturing and sales, Service-based subscription (Biobanking), B2B services (CDMO), Licensing and R&D

SuppliersAccredited hospitals and birth centers, Informed consent birth material donors, Specialized medical couriers, Laboratory equipment and reagent suppliers

CustomersSurgical and wound care distributors, Hospital systems, Expectant parents, Biotechnology licensing partners

CountryUnited States of America

Listed2021

Employees225.0

CEORobert Joseph Hariri

SectorHealthcare

IndustryBiotechnology

Websitecelularity.com

FilingsSEC EDGAR

Questions, answered.

What is Celularity's market cap?: Celularity (CELU) has a market capitalization of $21.6M and trades on NASDAQ.
Who are Celularity's competitors?: Celularity's key competitors include Organogenesis Holdings Inc., Longeveron, Mimedx Group, Inc., and others. These companies compete in similar markets and product categories.
Who does Celularity partner with?: Celularity's notable partners include BioCellgraft, Inc., Defeye, Inc., Celeniv Pte. Ltd..
What subsidiaries does Celularity have?: Celularity's subsidiaries include CariCord Inc..
Where is Celularity headquartered?: Celularity is headquartered in United States of America and employs approximately 225 people. It has been publicly traded since 2021.